CompletedNot Applicable

Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit

South Korea1,500 participantsStarted 2005-01

Plain-language summary

To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients admitted to or transferred to the SICU. * Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU. * Provide written informed consent Exclusion Criteria: * Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase inhibitors. * Females who are pregnant and breast feeding * Any underlying conditions or non-infectious diseases that will be ultimately fatal within 48 hours. * Those who have already been participating other clinical study related with antibiotics.

Trial details

NCT IDNCT00167960

SponsorWyeth is now a wholly owned subsidiary of Pfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

View on ClinicalTrials.gov More Gram-Positive Bacterial Infections trials